321 related articles for article (PubMed ID: 32495274)
21. Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection.
Zeuli JD; Rivera CG; Smith BL; Otto A; Temesgen Z
Drugs Today (Barc); 2022 Dec; 58(12):555-576. PubMed ID: 36651065
[TBL] [Abstract][Full Text] [Related]
22. Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the
Jeffrey JL; St Clair M; Wang P; Wang C; Li Z; Beloor J; Talarico C; Fridell R; Krystal M; White CT; Griffith S; D'Amico R; Smith K; Van Eygen V; Vingerhoets J; Vandermeulen K; Spreen W; van Lunzen J
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0170221. PubMed ID: 34978890
[TBL] [Abstract][Full Text] [Related]
23. First Extended-Release Injectable Drug Therapy for HIV.
Aschenbrenner DS
Am J Nurs; 2021 May; 121(5):24-25. PubMed ID: 33872258
[TBL] [Abstract][Full Text] [Related]
24. People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?
Bartalucci C; Baldi F; Ricci E; Orofino G; Menzaghi B; Ferrara S; Pellicano' GF; Squillace N; Sarchi E; Pontali E; Cenderello G; Bargiacchi O; Piccica M; Carleo MA; Cascio A; De Socio GV; Bonfanti P; Di Biagio A
AIDS; 2024 Mar; 38(3):430-434. PubMed ID: 38300162
[TBL] [Abstract][Full Text] [Related]
25. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine.
Hodge D; Back DJ; Gibbons S; Khoo SH; Marzolini C
Clin Pharmacokinet; 2021 Jul; 60(7):835-853. PubMed ID: 33830459
[TBL] [Abstract][Full Text] [Related]
27. Favorable Virological Outcome, Characteristics of Injection Site Reactions, Decrease in Renal Function Biomarkers in Asian People with HIV Receiving Long-Acting Cabotegravir Plus Rilpivirine.
Adachi E; Saito M; Otani A; Koga M; Yotsuyanagi H
AIDS Res Hum Retroviruses; 2024 Apr; 40(4):216-222. PubMed ID: 38164081
[TBL] [Abstract][Full Text] [Related]
28. Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy.
Corado KC; Caplan MR; Daar ES
Drug Des Devel Ther; 2018; 12():3731-3740. PubMed ID: 30464404
[TBL] [Abstract][Full Text] [Related]
29. Doravirine: First Global Approval.
Deeks ED
Drugs; 2018 Oct; 78(15):1643-1650. PubMed ID: 30341683
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Aboud M; Orkin C; Podzamczer D; Bogner JR; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Blair EA; Adkison K; Underwood M; Matthews JE; Wynne B; Vandermeulen K; Gartland M; Smith K
Lancet HIV; 2019 Sep; 6(9):e576-e587. PubMed ID: 31307948
[TBL] [Abstract][Full Text] [Related]
31. The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions.
Rusconi S; Santoro MM; Capetti AF; Gianotti N; Zazzi M
Int J Antimicrob Agents; 2022 Sep; 60(3):106627. PubMed ID: 35760225
[TBL] [Abstract][Full Text] [Related]
32. Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection.
Mehta R; Wolstenholme A; Di Lullo K; Fu C; Joshi S; Crauwels H; Givens N; Vanveggel S; Wynne B; Adkison K
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987139
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
Letendre SL; Mills A; Hagins D; Swindells S; Felizarta F; Devente J; Bettacchi C; Lou Y; Ford S; Sutton K; Shaik JS; Crauwels H; D'Amico R; Patel P
J Antimicrob Chemother; 2020 Mar; 75(3):648-655. PubMed ID: 31873746
[TBL] [Abstract][Full Text] [Related]
34. Fostemsavir: First Approval.
Markham A
Drugs; 2020 Sep; 80(14):1485-1490. PubMed ID: 32852743
[TBL] [Abstract][Full Text] [Related]
35. Cabotegravir-Rilpivirine: The First Complete Long-Acting Injectable Regimen for the Treatment of HIV-1 Infection.
Durham SH; Chahine EB
Ann Pharmacother; 2021 Nov; 55(11):1397-1409. PubMed ID: 33593093
[TBL] [Abstract][Full Text] [Related]
36. Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
Murray M; Antela A; Mills A; Huang J; Jäger H; Bernal E; Lombaard J; Katner H; Walmsley S; Khuong-Josses MA; Hudson K; Dorey D; Griffith S; Spreen W; Vanveggel S; Shaefer M; Margolis D; Chounta V
AIDS Behav; 2020 Dec; 24(12):3533-3544. PubMed ID: 32447500
[TBL] [Abstract][Full Text] [Related]
37. Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice.
Borghetti A; Farinacci D; Ciccullo A; Dusina A; Moschese D; Iannone V; D'Angelillo A; Lombardi F; Donne VD; Massaroni V; Visconti E; Tamburrini E; Di Giambenedetto S
J Med Virol; 2022 Oct; 94(10):4970-4974. PubMed ID: 35638227
[TBL] [Abstract][Full Text] [Related]
38. Formulation and pharmacology of long-acting cabotegravir.
Trezza C; Ford SL; Spreen W; Pan R; Piscitelli S
Curr Opin HIV AIDS; 2015 Jul; 10(4):239-45. PubMed ID: 26049948
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.
Charpentier C; Storto A; Soulié C; Ferré VM; Wirden M; Joly V; Lambert-Niclot S; Palich R; Morand-Joubert L; Landman R; Lacombe K; Katlama C; Ghosn J; Marcelin AG; Calvez V; Descamps D
J Antimicrob Chemother; 2021 Oct; 76(11):2983-2987. PubMed ID: 34015097
[TBL] [Abstract][Full Text] [Related]
40. Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE).
Czarnogorski M; Garris CP; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
J Int AIDS Soc; 2022 Sep; 25(9):e26003. PubMed ID: 36094142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
